Answers are grounded in this paper and cite their sources.
Patients with celiac disease (CD), particularly those whose disease is undiagnosed or who do not adhere to a gluten-free diet, may be exposed to various health risks, the most serious of which is malignancy. Many reports of patients with lymphoma in association with steatorrhea appeared in the early literature, but before 1961 malabsorption was always attributed to the presence of the tumor. In 1962, however, it was proposed that lymphoma is a complication of CD and that the mucosal lesion is premalignant. Further observations strengthened this hypothesis. Subsequently, other malignant tumors were found in association with CD and an increased incidence of gastrointestinal cancer, in general, and carcinoma of the esophagus, in particular, was reported. Carcinoma of the small bowel in association with CD is now known to be the second most common invasive malignancy after lymphoma. All of this work has been reviewed (1,2). An impressive amount of information exists about CD and malignancy, but there is much still to explore. Can lymphoma be prevented? What type of lymphoma is it? What is the relationship of a flat small-intestinal biopsy to lymphoma? And is chronic ulceration of the bowel part of the spectrum of lymphoma? Is there a place for screening programs to identify undiagnosed patients potentially at risk, who might derive benefit from a gluten-free diet? What constitutes a gluten-free diet, and what do patients themselves wish to know about the malignant risk? All these questions require attention. LYMPHOMA Prevalence The prevalence of lymphoma as a complication of CD is unknown for a number of reasons. Thus, the prevalence of CD itself in the community is uncertain, and lymphoma may be missed if autopsies are not routinely carried out. Some patients with established lymphoma may have CD, but the diagnosis is not usually pursued in this group (3). Data coming from referral centers will not necessarily reflect the situation in the general population, and it is likely that the prevalence is changing with the wider use of a gluten-free diet. While there are clearly reservations about the data, information on prevalence is available for groups of patients who have been followed up for many years (Table 1)(4-7,9). Clinical Presentation Patients with CD in whom lymphoma has developed may come to our attention in one of two ways. One group comprises those with established CD who initially respond to a gluten-free diet but later deteriorate because of the onset of cancer. In the second group CD and malignancy are found together or at about the same time. Whether this latter group, with flat biopsy results and malignancy, has CD has been the subject of considerable controversy. The weight of evidence indicates that they do and that the development of malignancy is the event that brings CD to light. When compared with uncomplicated cases of CD, this group has a similar HLA antigen profile (8,10), similar changes in intraepithelial subsets (11), and a similar incidence of hyposplenism. A recent immunohistochemical study of enteropathy-associated T-cell lymphoma also supports this view (12). In some patients the presentation is acute, manifesting in, for example, intestinal perforation or obstruction, bleeding from a tumor, or an opportunistic infection. In the majority of cases, however, the illness is insidious. At the diagnosis of lymphoma, the tumor is usually wide-spread, and the prognosis is very poor. Diagnosis The diagnosis of lymphoma arising in the context of CD can be difficult to make and may be delayed, because the presenting features are often nonspecific and indistinguishable from uncomplicated CD itself, either at diagnosis or in relapse. Many hematological and biochemical abnormalities are present, but no pattern emerges to permit early diagnosis. A progressive rise in serum IgA concentration may be found, but this is also seen in CD without malignancy. Increased levels of lysozyme have been noted, but they are not a reliable indicator of lymphoma. Differences in the small-intestinal mucosa of those with uncomplicated CD and those in whom lymphoma eventually develops have been sought. Lower plasma cell and higher lymphocyte counts in the lamina propria, lower lymphocyte counts in the epithelium, hypoplastic crypts, and histiocytic aggregates have all been cited as features. These observations, however, are unlikely to be helpful in individual cases. Upper-gastrointestinal endoscopy, which is now the preferred method of diagnosing CD, allows for diagnosis of lesions in the esophagus, stomach, and proximal bowel. Bowel radiology should always be carried out. Multiple irregular narrowed segments are characteristic of small-intestinal involvement with lymphoma, but appearances can be difficult to interpret. The place of scanning techniques is still to be determined, but they will detect the presence of mesenteric lymph node cavitation, which may be mistaken for lymphoma (13). Laparotomy may be necessary when the presence of cancer is suspected and a firm diagnosis has not been made. This can be a difficult procedure in the case of a debilitated patient, and it should not be undertaken lightly. Occasionally at laparotomy an isolated lesion can be resected, with good results. Pathology Tumors are usually located in the jejunum but may be found in the ileum, stomach, and colon. The primary tumor may be present in extragastrointestinal sites, such as the thyroid, liver, or peripheral lymph nodes. Occasionally at autopsy no gross lesion is found, but only microscopic foci of lymphoma. The lymphoma is derived from T lymphocytes. Attention has also focused on intraepithelial lymphocytes. A monoclonal antibody, HML-1, developed against intraepithelial lymphocytes also stains cells of lymphoma-complicating CD (14). It is possible that enteropathy-associated T-cell lymphoma derives from intraepithelial lymphocytes and that a small-cell lymphoma arising from these cells forms an intermediate stage in the development of the large-cell tumor (15). CARCINOMA OF THE SMALL BOWEL Until recently carcinoma of the small bowel as a complication of CD was thought to be rare, but a British collaborative study showed this to be the second most common invasive malignancy after lymphoma (10). Anemia is the most usual initial feature and is often associated with overt or occult blood loss. Weight loss, abdominal pain, and intestinal obstruction are also prominent features. If the tumor is in the proximal duodenum, it may be seen at endoscopy. A barium series will usually be helpful in locating the lesion. Long-term survival may occur if resection is carried out while the tumor is still confined to the bowel. MALIGNANCY IN OTHER GROUPS WITH CELIAC DISEASE Dermatitis Herpetiformis Patients with dermatitis herpetiformis have a higher than normal risk of malignancy. The relative risk of lymphoma in this group has been reported as 100 (16). Relatives of Patients with Celiac Disease Because CD is a genetically determined and complicated by lymphoma, it might be expected that more deaths from lymphoma would be seen in families of patients with CD. In the only study to address this problem, a significant increase in deaths from malignancy was found among family members of patients with CD (17). No increase in lymphoma was observed, but there was a higher rate of esophageal carcinoma in men. Studies of this type are difficult to carry out, and the results must be interpreted with caution. Ulcerative Jejuno-ileitis This is an uncommon and poorly understood complication of CD, in which chronic ulcers are found mainly in the jejunum and ileum but occasionally in the colon (18). Ulcerative jejuno-ileitis may bring a patient with CD to diagnosis and, as may happen with lymphoma, cause deterioration in patients with CD whose disease was controlled on a gluten-free diet. This condition can be difficult to differentiate from bowel lymphoma both clinically and radiologically. The disorders may coexist in one patient, and sometimes ulceration will be diagnosed before lymphoma becomes apparent. EFFECT OF A GLUTEN-FREE DIET ON MALIGNANCY At diagnosis, lymphoma is nearly always widespread, and the prognosis is therefore very poor: survival is measured in weeks to months. Earlier diagnosis of lymphoma, which would allow for a better prognosis, is not feasible at present, and predicting which CD patients will develop cancer is not possible either. Attention has therefore turned to prevention and the role that a gluten-free diet might play. Certain aspects of the small-intestinal mucosa indicate that it shows premalignant characteristics with respect to both lymphoma and carcinoma. These features include more numerous mitoses in the crypts and lymphoid cells and irregularity and increased basophilia in the surface epithelium. In addition, the mucosa in untreated CD is abnormally permeable and may also be deficient in carcinogen-detoxifying enzymes. These disturbances may allow carcinogens to penetrate the mucosa. A gluten-free diet restores the structure and function of the mucosa toward normal and hence might reduce the malignant potential. To try to answer the question of whether a gluten-free diet reduces the risk of malignancy, a series of patients from one clinic has been kept under long-term close surveillance (19). The analysis compared cancer morbidity among the patients with that observed in the general population using the method of years at risk. The expected number of tumors was calculated and compared with the number observed (Table 2). A twofold risk of cancer was found among the patients with CD, mainly tumors of the mouth, pharynx, and esophagus and non-Hodgkin lymphoma. Of the 210 patients in the series, 108 had followed a strict gluten-free diet, while the remainder were on a normal or reduced gluten diet. For those who had followed a strict gluten-free diet for ≥5 consecutive years, the overall risk of malignancy was not significantly increased when compared with that of the general population. For those ingesting gluten, however, there was a significantly increased risk (Table 2). No differences could be detected for individual sites or types (mouth, pharynx, or esophagus and lymphoma), but when these were combined, the difference between the relative risks (6.7 for those on a strict gluten-free diet and 38.7 for those ingesting gluten) was significant (p < 0.05). Excess morbidity was also calculated and was clearly related to the amount of gluten ingested (Table 3). The decreasing trend in higher morbidity rates with increasing adherence to a gluten-free diet was significant (p < 0.01). These results, combined with anecdotal evidence from other CD clinics, indicate that a gluten-free diet does protect against malignancy and is another reason to advise all patients to adhere to a strict gluten-free diet for life. WHAT CONSTITUTES A GLUTEN-FREE DIET? A gluten-free diet based on cornstarch contains very small amounts of gluten. Within the context of malignancy, it is not known whether these small quantities are harmful to patients, although it could be argued from the evidence that a diet completely free of gluten should be pursued. Wheat-free products that are palatable and competitively priced are available, and it is likely that an increasing demand for them will come from patients themselves. Screening for Celiac Disease Screening specific groups of people who might be at high risk of CD or even large general populations is possible. It is evident from these studies that patients who are symptomatic and can benefit from a gluten-free diet can be identified. On the other hand, many patients are without symptoms. If a gluten-free diet reduces the risk of malignancy, then identifying patients with CD and starting them on such a diet should be beneficial. Clearly there are both medical and ethical issues to consider here. Approach to Patients Patients are becoming increasingly aware of a link between CD and malignancy and wish for further information. It is now possible to adopt an encouraging and positive attitude and advise patients that on current evidence, the best insurance against the development of this complication is strict adherence to a gluten-free diet. This is a sensitive area, and a careful approach to patients is required so that they do not become unduly worried.
No takes yet. Share an insight, caveat, or question.
G. K. T. Holmes (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: